Lisata Therapeutics Inc. (LSTA)
Lisata Therapeutics Statistics
Share Statistics
Lisata Therapeutics has 8.62M shares outstanding. The number of shares has increased by 1.05% in one year.
| Shares Outstanding | 8.62M |
| Shares Change (YoY) | 1.05% |
| Shares Change (QoQ) | 0.91% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 6.73M |
| Failed to Deliver (FTD) Shares | 540 |
| FTD / Avg. Volume | 1.2% |
Short Selling Information
The latest short interest is 17.06K, so 0.2% of the outstanding shares have been sold short.
| Short Interest | 17.06K |
| Short % of Shares Out | 0.2% |
| Short % of Float | 0.26% |
| Short Ratio (days to cover) | 1.79 |
Valuation Ratios
The PE ratio is -1.24 and the forward PE ratio is -1.17. Lisata Therapeutics's PEG ratio is 0.18.
| PE Ratio | -1.24 |
| Forward PE | -1.17 |
| PS Ratio | 24.82 |
| Forward PS | 0.4 |
| PB Ratio | 0.84 |
| P/FCF Ratio | -1.28 |
| PEG Ratio | 0.18 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Lisata Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.16, with a Debt / Equity ratio of 0.
| Current Ratio | 6.16 |
| Quick Ratio | 6.16 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.68% and return on capital (ROIC) is -73.5%.
| Return on Equity (ROE) | -0.68% |
| Return on Assets (ROA) | -0.57% |
| Return on Capital (ROIC) | -73.5% |
| Revenue Per Employee | $40,000 |
| Profits Per Employee | $-799,400 |
| Employee Count | 25 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -798K |
| Effective Tax Rate | 0.04 |
Stock Price Statistics
The stock price has increased by -33.33% in the last 52 weeks. The beta is 1.15, so Lisata Therapeutics's price volatility has been higher than the market average.
| Beta | 1.15 |
| 52-Week Price Change | -33.33% |
| 50-Day Moving Average | 2.89 |
| 200-Day Moving Average | 3.02 |
| Relative Strength Index (RSI) | 29.6 |
| Average Volume (20 Days) | 45.09K |
Income Statement
In the last 12 months, Lisata Therapeutics had revenue of 1M and earned -19.98M in profits. Earnings per share was -2.4.
| Revenue | 1M |
| Gross Profit | 1M |
| Operating Income | -22.41M |
| Net Income | -19.98M |
| EBITDA | 0 |
| EBIT | -22.41M |
| Earnings Per Share (EPS) | -2.4 |
Balance Sheet
The company has 16.21M in cash and 0 in debt, giving a net cash position of 16.21M.
| Cash & Cash Equivalents | 16.21M |
| Total Debt | 0 |
| Net Cash | 16.21M |
| Retained Earnings | -548.07M |
| Total Assets | 38.2M |
| Working Capital | 33M |
Cash Flow
In the last 12 months, operating cash flow was -19.36M and capital expenditures 0, giving a free cash flow of -19.36M.
| Operating Cash Flow | -19.36M |
| Capital Expenditures | 0 |
| Free Cash Flow | -19.36M |
| FCF Per Share | -2.32 |
Margins
Gross margin is 100%, with operating and profit margins of -2.24K% and -2K%.
| Gross Margin | 100% |
| Operating Margin | -2.24K% |
| Pretax Margin | -2.08K% |
| Profit Margin | -2K% |
| EBITDA Margin | n/a |
| EBIT Margin | -2.24K% |
| FCF Margin | -1.94K% |
Dividends & Yields
LSTA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -111.11% |
| FCF Yield | -103.96% |
Analyst Forecast
The average price target for LSTA is $15, which is 594.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 594.4% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Sep 15, 2022. It was a backward split with a ratio of 1:15.
| Last Split Date | Sep 15, 2022 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -18.38 |
| Piotroski F-Score | 1 |